Entity

Gain Therapeutics

Biotechnology - Therapeutics and Diagnostics

 

Gain Therapeutics develops next generation pharmacological chaperones for the treatment of devastating rare diseases. Building on Minoryx’s experience, Gain Therapeutics applies the SEE-Tx platform to identify small drug-like molecules that bind to specific enzymes, stabilizing their structure without competing with the natural substrate. In this manner, we can recover essential enzymes that are malfunctioning in certain inborn errors of metabolism. We have five active programs, including GM1 Gangliosidosis and Gaucher’s Disease.

 

Funded by private Swiss investors and the TiVenture fund, Gain Therapeutics is based in Lugano (Switzerland), with a team of researchers and the scientific direction operating in the Barcelona Science Park.

info@gaintherapeutics.com

gaintherapeutics.com


Contact person: Xavier Barril Alonso

Location: Ed. Clúster - 01C64